Document is current
Any future updates will be listed below
-
Authors
Brisuda, Antonín
Ho, James C. S. https://orcid.org/0000-0002-6131-1297
Kandiyal, Pancham S.
Ng, Justin T-Y.
Ambite, Ines https://orcid.org/0000-0003-1470-671X
Butler, Daniel S. C. https://orcid.org/0000-0002-6717-545X
Háček, Jaromir
Wan, Murphy Lam Yim
Tran, Thi Hien
Nadeem, Aftab
Tran, Tuan Hiep
Hastings, Anna https://orcid.org/0000-0002-2236-1232
Storm, Petter
Fortunati, Daniel L.
Esmaeili, Parisa
Novotna, Hana
Horňák, Jakub
Mu, Y. G. https://orcid.org/0000-0002-2499-026X
Mok, K. H. https://orcid.org/0000-0003-3663-2002
Babjuk, Marek
Svanborg, Catharina https://orcid.org/0000-0001-8145-0553
-
Funding
Funding for this research was provided by:
Cancerfonden
EC | Horizon 2020 Framework Programme (954360)
Vetenskapsrådet
HAMLET Pharma
- License Information
-
More Information
Article History
Received: 8 April 2020
Accepted: 15 April 2021
First Online: 8 June 2021
Competing interests
: C.S. holds shares in HAMLET Pharma, as a representative of scientists in the HAMLET group. Patents protecting the use of the alpha1 peptide were filed previously (Biologically active complexes and therapeutic uses thereof; GB 201707715 priority date 14/05/2017, PCT/EP2018/062396 filing date 14/05/2018; inventors: C.S., A.N., J.Ho). No specific patents have been filed based on this study. Other authors declare no competing or conflicts of interests.
